

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2018

Seite 1

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 17: Hepatozelluläres Karzinom – aktuelle Therapiekonzepte.

Von Dr. Tobias Werner, Dr. Lars Stiedenroth, Dr. Suad Jaganjac, Prof. Dr. Götz von Wichert

1. Bruix J, Sherman M. Management of Hepatocellular Carcinoma: An Update. *Hepatology* 2011;53:1020-102.
2. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma. *Hepatology* 2005;42:1208-36.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer: EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. *Hepatology* 2012;56:908-943.
4. Luedde T, Kaplowitz N, Schwabe R.F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance. *Gastroenterology*. 2014;147:765–783.
5. Boege Y, Malehmir M, Healy ME, Bettermann K, Lorentzen A, Vucur M, Ahuja AK, Böhm F, Mertens JC et al., Weber A. A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer Development. *Cancer Cell*. 2017;32(3):342-359.
6. El-Serag HB. Hepatocellular Carcinoma. *N Engl J Med* 2011;365:1118-1127.
7. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet*. 2018 Jan 4. pii: S0140-6736(18)30010-2.
8. Forner A, Reig ME, Rodriguez de Lope, Bruix J. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. *Semin Liver Dis* 2010;30:61-74.
9. Freeman RB, Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. *Hepatology* 2008;47:1052-1057.
10. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010;33:41-52.
11. Lammer J, Malgari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective random-ised study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010;33:41-52.
12. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. *Eur J Gastroenterol Hepatol* 2010;22:391-398.
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma. *Semin Liver Dis* 2010;30:52-60.
14. Peck-Radosavljevic M. Imaging and early diagnosis of hepatocellular carcinoma. *Minerva Gastroenterol Dietol* 2011;57:273-286.
15. Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M, Massironi S, et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. *Gut* 2010;59:638-644.
16. Glantzounis GK, Paliouras A, Stylianidi MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G, Felekouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. *Eur J Surg Oncol*. 2018 Feb;44(2):195-208.
17. Brouquet A, Andreou A, Shindoh J, Vauthey JN. Methods to improve resectability of hepatocellular carcinoma. *Recent Results Cancer Res*. 2013;190:57-67.
18. Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. *J Gastroenterol Hepatol*. 2018 Feb;33(2):347-354.

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2018

Seite 2

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

19. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009;10:35-43.
20. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996;334:693-699.
21. Neuberger J. Liver allocation for patients with hepatocellular carcinoma. *Liver Transpl* 2010;16:249-251.
22. Guo W, He X, Li Z, Li Y. Combination of Transarterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA) vs. Surgical Resection (SR) on Survival Outcome of Early Hepatocellular Carcinoma: A Meta-Analysis. *Hepatogastroenterology*. 2015 May;62(139):710-4.
23. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology* 2003;37:429-442.
24. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G. SARAH Trial Group Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. *Lancet Oncol*. 2017 Dec;18(12):1624-1636.
25. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al. for the SHARP Investigators Study Group: Sorafenib in Advanced Hepatocellular Carcinoma. *NEJM* 2008;259:378-390.
26. Schott E., Ebert MP, Trojan J: Treatment of Hepatocellular Carcinoma with Sorafenib – Focus on Special Populations and Adverse Event Management. *Z Gastroenterol*. 2012 Sep;50(9):1018-27.
27. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G. RESORCE Investigators Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Jan 7;389(10064):56-66.

S. 28-31: Contergan – Gesundheitsrisiken nehmen mit dem Alter stärker zu. *Von Dr. Rudolf Beyer*

1. Lenz W. A short history of thalidomide embryopathy. *Teratology* 1988; 38(3):203–215.
2. Kirk B. Der Contergan-Fall: eine unvermeidbare Arzneimittelkatastrophe?: Zur Geschichte des Arzneistoffs Thalidomid: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart; 1999
3. Schuler-Faccini L, Soares RCF, Sousa ACM de, et al. New cases of thalidomide embryopathy in Brazil. *Birth defects research. Part A, Clinical and molecular teratology* 2007; 79(9):671–672.
4. Kruse A, Greiner CD, et al. Contergan - Endbericht an die Conterganstiftung für behinderte Menschen; 2012. http://www.contergan-infoportal.de/fileadmin/downloads/NEU-DOWNLOADS/Dokumentation/Contergan_Endbericht_Universitaet_Heidelberg.pdf

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2018

Seite 3

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

- Smithells RW, Newman CG. Recognition of thalidomide defects. *Journal of Medical Genetics* 1992;29(10):716–723.
- Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. *Birth defects research. Part C, Embryo today reviews* 2015;105(2):140–156.
- K. M. Peters, C. Albus, M. Lungen, A. Niecke, H. Pfaff CS. Gesundheitsschäden, psychosoziale Beeinträchtigungen und Versorgungsbedarf von contergangeschädigten Menschen aus Nordrhein-Westfalen in der Langzeitperspektive.: Gutachten im Auftrag des LZG.NRW; 2016. https://www.lzg.nrw.de/_media/pdf/service/Pub/2015_druckfrisch/LZG_NRW_Gutachten_Contergan_Abschlussbericht_ue_2016.pdf
- Ghassemi Jahani SA, Danielson B, Karlsson J, Danielsson AJ. Long-term follow-up of thalidomide embryopathy: malformations and development of osteoarthritis in the lower extremities and evaluation of upper extremity function. *Journal of children's orthopaedics* 2014;8(5):423–433.
- Neuhauser H, Thamm M, Ellert U. Blutdruck in Deutschland 2008-2011 Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz* 2013;56(5-6):795–801.
- Icks A, Rathmann W, Rosenbauer J. Gesundheitsberichterstattung des Bundes Heft 24 Diabetes mellitus. Berlin; 2005
- Shiga T, Shimbo T, Yoshizawa A. Multicenter investigation of lifestyle-related diseases and visceral disorders in thalidomide embryopathy at around 50 years of age. *Birth defects research. Part A, Clinical and molecular teratology* 2015;103(9):787–793.
- Leibiger A, Weisser B, Grünhagen M, Köhler M. Einfluss einer Maßnahme zur betrieblichen Gesundheitsförderung mit Einsatz von Schrittzählern zur Senkung kardiovaskulärer Risikofaktoren (Schrittzählerstudie —DAMP plus 3000!fi). *Journal für Hypertonie - Austrian Journal of Hypertension* 2012(4): 12–17
- Denkinger MD. Wenn es um Prävention geht, zählt jeder Schritt: Körperliche Aktivität bis ins hohe Alter. *MWW Fortschritte der Medizin* 2008;150(45).
- Yoshizawa A, et al. Behandlung von contergangeschädigten Menschen F & A (Q&A on Thalidomide-Impaired People). National Center for Global Health Toyama, Japan; 2014. http://www.contergan-infoportal.de/fileadmin/downloads/NEU-DOWNLOADS/Medizinische_Beitraege/japanische_Studie.pdf
- Kowalski TW, Sanseverino MTV, Schuler-Faccini L, Vianna FSL. Thalidomide embryopathy: Follow-up of cases born between 1959 and 2010. *Birth defects research. Part A, Clinical and molecular teratology* 2015;103(9):794–803.
- Nallegowda M, Lee E, Brandstater M, et al. Amputation and cardiac comorbidity: analysis of severity of cardiac risk. *PM & R the journal of injury, function, and rehabilitation* 2012;4(9):657–666.
- Niecke A, Peters K, Samel C, et al. Mental Disorders in People Affected by Thalidomide. *Deutsches Ärzteblatt international* 2017; 114(10):168–174.
- Cuffee Y, Ogedegbe C, Williams NJ, et al. Psychosocial risk factors for hypertension: an update of the literature. *Current hypertension reports* 2014;16(10):483.
- Sanz J, García-Vera MP, Espinosa R, et al. Psychological factors associated with poor hypertension control: differences in personality and stress between patients with controlled and uncontrolled hypertension. *Psychological reports* 2010;107(3):923–938.
- Gale CR, Batty GD, Osborn DPJ, et al. Mental disorders across the adult life course and future coronary heart disease: evidence for general susceptibility. *Circulation* 2014;129(2):186–193.

Literaturverzeichnis

Hamburger Ärzteblatt 04 | 2018

Seite 4

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

21. Schulte-Hillen J, Beyer R. Abstractband 40. Wissenschaftlicher Kongress - Deutsche Hochdruckliga e. V. DHL® / Deutsche Gesellschaft für Hypertonie und Prävention. Med Welt 2016. [http://www.schattauer.de/de/magazine/uebersicht/zeitschriften-a-z/die-medizinische-welt/inhalt/archiv/issue/2427/manuscript/26908/download.html\(6\)](http://www.schattauer.de/de/magazine/uebersicht/zeitschriften-a-z/die-medizinische-welt/inhalt/archiv/issue/2427/manuscript/26908/download.html(6))
22. Wesseling KH. Finapres - Kontinuierliche, nichtinvasive arterielle Blutdruckmessung am Finger nach der Methode von Peñáz. W. Meyer-Sabellek et al. (eds.), Indirekte 24-Stunden Blutdruckmessung. Springer-Verlag Berlin Heidelberg 1988.

S. 32-33: Fieber unklarer Ursache. *Von Katarina Krüger, Dr. Hans-Otto Wagner, Dr. Romy Wollstein, Prof. Dr. Martin Scherer*

1. Naito T, et al. „Diagnostic workup for fever of unknown origin: a multicenter collaborative retrospective study.“ *BMJ Open* 2013;3:e003971.
2. Efstathiou SP, et al. „Fever of unknown origin: Discrimination between infectious and non-infectious causes.“ *European Journal of Internal Medicine*, Volume 21, Issue 2, 137–143.
3. Takeda R, et al. „Key Diagnostic Features of Fever of Unknown Origin: Medical History and Physical Findings.“ *Journal of General and Family Medicine*, 18.3 (2017):131–134.
4. Simon L, et al. „Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-analysis.“ *Clinical Infectious Diseases*, Volume 39, Issue 2, 15 July 2004, Pages 206–217
5. Mahroum N, et al. „Diagnosis and classification of adult Still's disease.“ *Journal of Autoimmunity*. Volumes 48–49, February–March 2014, Pages 34-37.
6. Govoni M, et al. „How I treat patients with adult onset Still's disease in clinical practice.“ *Autoimmunity Reviews*. Volume 16, Issue 10, October 2017, Pages 1016-1023.
7. Gerfaud-Valentin M, et al. „Adult-onset Still's disease“. *Autoimmunity Reviews*. Volume 13, Issue 7, July 2014, Pages 708-722.

S. 36-37: Wanderer, kommst Du nach Tönning... *Von Oswald Müller-Plathe*

1. Schmidt H. (Hrsg). Die Jugenderinnerungen des Chirurgen Friedrich von Esmarch. Westholsteinische Verlagsanstalt Boyens u. Co, Heide, 1938.
2. Ziesing D. Das Zündnadelgewehr im Verbandskasten oder die unglaubliche Geschichte des Dreiecktuches. *Zeitschr. F. Heereskunde*. 452, 4/2014.
3. Esmarch F. Deutscher Samariter-Verein. *Die Gartenlaube* 14, 236-238, 1882.
4. Wikipedia: Gustav Adolf Neuber
5. Konjetzny GE, Heits E. *Gustav Adolf Neuber und die Asepsis*. Enke, Stuttgart 1950.
6. Bier A. *Friedrich von Esmarch. Der Chirurg* 1935, Heft 9 (leicht veränderte Fassung in lit.1).